D.A. Davidson & CO. Takes Position in Astrana Health, Inc. (NASDAQ:ASTH)

D.A. Davidson & CO. acquired a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 26,565 shares of the company’s stock, valued at approximately $1,539,000.

Several other institutional investors have also recently added to or reduced their stakes in ASTH. GAMMA Investing LLC acquired a new position in Astrana Health during the third quarter worth $34,000. Nisa Investment Advisors LLC acquired a new position in Astrana Health during the 3rd quarter worth about $35,000. KBC Group NV purchased a new position in Astrana Health during the 3rd quarter valued at about $70,000. Quest Partners LLC acquired a new position in Astrana Health in the 3rd quarter valued at about $133,000. Finally, Central Pacific Bank Trust Division purchased a new stake in Astrana Health during the third quarter worth about $160,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on ASTH shares. TD Cowen started coverage on shares of Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price objective for the company. KeyCorp assumed coverage on shares of Astrana Health in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. BTIG Research increased their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Robert W. Baird boosted their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Truist Financial increased their price target on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $65.17.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $43.25 on Friday. The firm has a market capitalization of $2.43 billion, a PE ratio of 33.27, a price-to-earnings-growth ratio of 1.99 and a beta of 1.24. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The business’s fifty day moving average price is $52.79 and its 200 day moving average price is $48.00. Astrana Health, Inc. has a 12 month low of $32.32 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter last year, the company earned $0.47 EPS. On average, sell-side analysts anticipate that Astrana Health, Inc. will post 1.17 earnings per share for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.